Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Gynecol Oncol. 2019 Feb 18;:
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Cancer. 2019 Feb 15;:
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Cancer Immunol Immunother. 2019 Feb 11;:
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Eur J Cancer. 2019 Mar;109:154-161
TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.
Int J Gynecol Cancer. 2019 Jan 18;:
Blood Adv. 2018 Dec 11;2(23):3506-3514
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Eur J Cancer. 2018 Dec 06;107:1-7
J Autoimmun. 2018 Oct 11;:
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Br J Cancer. 2018 Sep 11;: